Physician profile
Glenna Howe
NPI 1245058882
$969.82
in general payments reported to CMS, 2019-2025
22 companies · $776 in 2025
The $776 reported for 2025 was more than what 81% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $194 · 2025: $776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $970.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $969.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $109.00 | 2025 | |
| Ucb, INC. | $103.20 | 2025 | Bimzelx |
| Janssen Biotech, INC. | $99.49 | 2024-2025 | Tremfya |
| Radius Health, INC. | $90.23 | 2024-2025 | Tymlos |
| Amgen INC. | $83.57 | 2024-2025 | Otezla, Tavneos, Otezla |
| Novartis Pharmaceuticals Corporation | $47.49 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $45.42 | 2025 | Saphnelo |
| Invivyd INC | $45.13 | 2025 | Pemgarda |
| Pfizer INC. | $38.59 | 2025 | |
| Tonix Medicines, INC. | $35.25 | 2025 | Tonmya |
| Genentech USA, INC. | $31.24 | 2025 | Actemra |
| Aurinia Pharma U.S., INC. | $28.86 | 2025 | Lupkynis |
| E.R. Squibb & Sons, L.L.C. | $28.67 | 2025 | Orencia |
| Almatica Pharma LLC | $27.59 | 2025 | Teriparatide |
| Organon LLC | $27.53 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $23.92 | 2025 | |
| Celltrion USA INC. | $21.82 | 2024 | Vegzelma |
| Lilly USA, LLC | $21.28 | 2024 | Taltz, Zepbound |
| Kiniksa Pharmaceuticals International, Plc | $16.74 | 2024 | Arcalyst |
| Biogen, INC. | $16.15 | 2024 | Tofidence |
| Sandoz INC. | $14.71 | 2025 | Hyrimoz |
| Tersera Therapeutics LLC | $13.94 | 2025 | Quzyttir |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenna Howe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.